C4 Therapeutics, Inc. Share Price & Technical Analysis
CCCC · $3.75 (+1.90%)
Healthcare / Biotechnology
$3.75
+1.90%
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology pr…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
29% return in May, -11% avg return in past 3 year May month.
69% return in 2026, 46% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 42% | 0% | 4% | 29% | – | – | – | – | – | – | – | 69% |
| 25 | -3% | -21% | -38% | 0% | -25% | 8% | 43% | 30% | -15% | 18% | 4% | -27% | -27% |
| 24 | 11% | 75% | -25% | -24% | -21% | -8% | 43% | -9% | -10% | -5% | -18% | -20% | -12% |
| 23 | 32% | -31% | -42% | -3% | 13% | -18% | 44% | -26% | -34% | -17% | 0% | 256% | 176% |
| 22 | -25% | -8% | 9% | -65% | -15% | 3% | 28% | 3% | -12% | 7% | -12% | -31% | -119% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$337.70M
P/E ratio
—
52W high
$3.95
52W low
$1.21
Volume
18,31,217
Beta
2.78
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is C4 Therapeutics, Inc. share price today?
- C4 Therapeutics, Inc. (CCCC) last traded around $3.75 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CCCC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CCCC. Download the app for real-time alerts.
- How can I analyze C4 Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.